SI9200260A - Lipophilic oligosaccharide antibiotic salt compostition - Google Patents
Lipophilic oligosaccharide antibiotic salt compostition Download PDFInfo
- Publication number
- SI9200260A SI9200260A SI19929200260A SI9200260A SI9200260A SI 9200260 A SI9200260 A SI 9200260A SI 19929200260 A SI19929200260 A SI 19929200260A SI 9200260 A SI9200260 A SI 9200260A SI 9200260 A SI9200260 A SI 9200260A
- Authority
- SI
- Slovenia
- Prior art keywords
- formula
- antibiotic
- pharmaceutically acceptable
- cyclodextrin
- hydroxypropyl
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77786491A | 1991-10-16 | 1991-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9200260A true SI9200260A (en) | 1993-06-30 |
Family
ID=25111545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI19929200260A SI9200260A (en) | 1991-10-16 | 1992-10-16 | Lipophilic oligosaccharide antibiotic salt compostition |
Country Status (26)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6380172B1 (en) | 1991-10-16 | 2002-04-30 | Schering Corporation | Monomeric lipophilic oligosaccharide antibiotic compositions |
| US5948688A (en) * | 1991-10-16 | 1999-09-07 | Schering Corporation | Method of determining monomeric drug content |
| US5652226A (en) * | 1995-12-22 | 1997-07-29 | Schering Corporation | Water soluble antibiotics |
| US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
| US5763600A (en) * | 1997-04-18 | 1998-06-09 | Schering Corporation | Oligosaccharide antibiotics and process for preparation thereof |
| JP2001518556A (ja) * | 1997-10-03 | 2001-10-16 | ガレニカ ファーマシューティカルズ， インコーポレイテッド | イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用 |
| US6162910A (en) * | 1998-11-30 | 2000-12-19 | Schering Corporation | Process for preparing lipophilic oligosaccharide antibiotics |
| AU2157200A (en) * | 1998-12-18 | 2000-07-12 | Schering Corporation | Process for recovering lipophilic oligosaccharide antibiotics |
| US6320044B1 (en) | 1998-12-18 | 2001-11-20 | Schering Corporation | Process for recovering lipophilic oligosaccharide antibiotics |
| AU2003201A (en) * | 1999-12-01 | 2001-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel use of lung surfactant |
| US6861513B2 (en) | 2000-01-12 | 2005-03-01 | Schering Corporation | Everninomicin biosynthetic genes |
| CA2726789A1 (en) * | 2000-02-05 | 2001-11-08 | Theravance, Inc. | Cyclodextrin containing glycopeptide antibiotic compositions |
| WO2002032459A2 (en) * | 2000-10-17 | 2002-04-25 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
| DE10109166A1 (de) * | 2001-02-25 | 2002-09-12 | Combinature Biopharm Ag | Avilamycin-Derivate |
| CA2560266A1 (en) * | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
| EP1977874A3 (en) * | 2004-12-01 | 2008-10-15 | Nitto Denko Corporation | Foam Filling Member |
| WO2006110810A2 (en) * | 2005-04-12 | 2006-10-19 | Panacos Pharmaceuticals, Inc. | Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine |
| AU2008299885C1 (en) * | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| JP2010095454A (ja) * | 2008-10-14 | 2010-04-30 | Cyclochem:Kk | 抗菌組成物 |
| WO2012097223A2 (en) * | 2011-01-14 | 2012-07-19 | Emory University | Oligosaccharide conjugates for targeting bacteria and uses related thereto |
| JP2018517046A (ja) | 2015-06-10 | 2018-06-28 | ビテス， インコーポレイテッド | ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法 |
| CN106317143B (zh) * | 2016-08-23 | 2020-10-30 | 河北圣雪大成制药有限责任公司 | 一种提取阿维拉霉素的方法 |
| CN118922484A (zh) | 2022-02-18 | 2024-11-08 | 贝伦治疗公益公司 | 羟丙基-β-环糊精的组合物和其纯化方法 |
| CN117024611B (zh) * | 2023-03-01 | 2024-05-17 | 中国科学院南海海洋研究所 | 寡糖类抗生素everninomicin高产菌株的构建及活性的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR128F (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1962-04-02 | |||
| US3915956A (en) * | 1973-07-09 | 1975-10-28 | Schering Corp | Reduction products of everninomicins and methods for their manufacture |
| US3920629A (en) * | 1973-09-19 | 1975-11-18 | Schering Corp | Desevernitrose everninomicins and method for their manufacture |
| US4006225A (en) * | 1973-10-31 | 1977-02-01 | Schering Corporation | Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor |
| US4027016A (en) * | 1976-01-19 | 1977-05-31 | Schering Corporation | Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor |
| US3998708A (en) * | 1976-01-19 | 1976-12-21 | Schering Corporation | Electrochemical process for preparing hydroxylaminoeverninomicins |
| US4129720A (en) * | 1977-02-14 | 1978-12-12 | Schering Corporation | Aminoeverninomicin and derivatives thereof |
| US4597968A (en) * | 1982-08-06 | 1986-07-01 | Schering Corporation | Antibiotic 13-384 complex from Micromonospora carbonacea var africana |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4735903A (en) * | 1984-06-21 | 1988-04-05 | Schering Corporation | Micromonospora carbonacea var africana |
| US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| US4622314A (en) * | 1985-10-15 | 1986-11-11 | Schering Corporation | Substituted oligosaccharide antibiotics |
| US4767748A (en) * | 1985-10-15 | 1988-07-30 | Schering Corporation | Substituted oligosaccharide antibodies |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
-
1992
- 1992-10-14 EP EP92309368A patent/EP0538011B1/en not_active Expired - Lifetime
- 1992-10-14 PH PH45109A patent/PH31675A/en unknown
- 1992-10-14 US US08/211,700 patent/US5624914A/en not_active Expired - Lifetime
- 1992-10-14 AU AU27806/92A patent/AU678344B2/en not_active Ceased
- 1992-10-14 DE DE69221252T patent/DE69221252T2/de not_active Expired - Fee Related
- 1992-10-14 PL PL92303189A patent/PL170591B1/pl unknown
- 1992-10-14 WO PCT/US1992/008565 patent/WO1993007904A1/en not_active Application Discontinuation
- 1992-10-14 JP JP5507719A patent/JP2614407B2/ja not_active Expired - Lifetime
- 1992-10-14 DK DK92309368.6T patent/DK0538011T3/da active
- 1992-10-14 YU YU92192A patent/YU48722B/sh unknown
- 1992-10-14 TW TW081108170A patent/TW221378B/zh active
- 1992-10-14 EP EP92921991A patent/EP0610295A1/en active Pending
- 1992-10-14 KR KR1019940701247A patent/KR100249584B1/ko not_active Expired - Fee Related
- 1992-10-14 AT AT92309368T patent/ATE156019T1/de not_active IP Right Cessation
- 1992-10-14 HU HU9401104A patent/HUT75157A/hu unknown
- 1992-10-14 CA CA002121345A patent/CA2121345C/en not_active Expired - Fee Related
- 1992-10-14 ZA ZA927923A patent/ZA927923B/xx unknown
- 1992-10-14 NZ NZ244735A patent/NZ244735A/en unknown
- 1992-10-14 ES ES92309368T patent/ES2104845T3/es not_active Expired - Lifetime
- 1992-10-15 IL IL10344692A patent/IL103446A/xx not_active IP Right Cessation
- 1992-10-15 CN CN92112388A patent/CN1035923C/zh not_active Expired - Fee Related
- 1992-10-15 MX MX9205922A patent/MX9205922A/es not_active IP Right Cessation
- 1992-10-16 HR HR07/777,864A patent/HRP921069B1/xx not_active IP Right Cessation
- 1992-10-16 SI SI19929200260A patent/SI9200260A/sl unknown
-
1994
- 1994-04-08 NO NO941276A patent/NO307326B1/no not_active IP Right Cessation
- 1994-04-14 FI FI941723A patent/FI941723A0/fi unknown
-
1997
- 1997-09-19 GR GR970402434T patent/GR3024800T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9200260A (en) | Lipophilic oligosaccharide antibiotic salt compostition | |
| CN102215690B (zh) | 抗微生物组合物 | |
| UA75083C2 (uk) | Похідні глікопептидфосфонатів | |
| CN113413389A (zh) | 一种组蛋白去乙酰化酶抑制剂的制剂及其制备方法和用途 | |
| US5776912A (en) | Lipophilic oligosaccharide antibiotic compositions | |
| JP7526175B2 (ja) | Ｂｃｌ－２阻害剤のシクロデキストリンに基づく製剤 | |
| JP3597239B2 (ja) | 安定な点眼剤 | |
| EP0399716B1 (en) | Hypoallergenic steroidal anesthetic/hypnotic compositions | |
| US7795207B2 (en) | Lipopeptide compositions | |
| EP0165123A2 (fr) | Dérivés lipophiles de muramylpeptides ayant des propriétés d'activation des macrophages, compositions les contenant et procédé pour les obtenir | |
| CN101370524A (zh) | 脂肽组合物 | |
| CA2371942A1 (en) | Pseudomycin antifungal compositions and methods for their use | |
| HK1001085B (en) | Lipophilic oligosaccharide antibiotic salt compositions | |
| EP1994938A1 (en) | New lipoglycodepsipeptide compositions | |
| AU2015276911A2 (en) | Methods for treating infections | |
| JPH05271237A (ja) | ランカシジン群抗生物質包接体 | |
| JPH02172913A (ja) | ポリプレニル系化合物含有注射剤 |